What Is the Price of Miaite (Pronidesivir)
Miaite, also known as Pronidesivir, is a groundbreaking antiviral medication specifically developed for the treatment of Feline Infectious Peritonitis (FIP). This disease, caused by a mutation of the feline coronavirus, manifests with symptoms such as loss of appetite, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological damage, and uveitis. The emergence of Miaite (Pronidesivir) has marked a significant milestone in veterinary medicine, offering hope for affected cats.
Miaite’s active ingredient, GS-441524, is recognized worldwide for its potent antiviral properties. It has demonstrated remarkable effectiveness in combating FIP by inhibiting viral replication. Although originally developed for human viral diseases, GS-441524 has been adapted into Miaite formulations suitable for feline use. The medication is administered orally, providing a safe, non-invasive, and rapid method to target the virus at its source.
In March 2026, the Lao Ministry of Agriculture and Forestry (MAF) officially approved Miaite (Pronidesivir) as a registered veterinary drug. It is the first FIP-specific treatment to receive official approval and registration in the country, ensuring quality assurance and safety standards. Miaite’s approval signifies its recognition as an effective, reliable, and officially sanctioned treatment for feline FIP worldwide.
The recommended dosage varies depending on the cat’s weight and clinical form of FIP. Typically, for standard cases, cats receive 15 mg per kilogram of body weight daily (half a tablet). For neurological or ocular types of FIP, the dose may be increased to 30 mg/kg, under veterinarian supervision. It is suggested to administer Miaite on an empty stomach—either an hour before or two hours after feeding—to maximize absorption.
The treatment duration is generally no less than 12 weeks. Adherence to the prescribed schedule is crucial, with missed doses potentially compromising treatment effectiveness. During therapy, owners should monitor their cats for changes in appetite, body temperature, activity levels, and overall health. Regular blood tests to assess liver and kidney function are recommended to ensure safety throughout the treatment course.
Miaite (Pronidesivir) is considered a relatively safe medication with minimal side effects when used appropriately. However, despite being available as an over-the-counter (OTC) product in some regions, it is strongly advised that owners consult with a veterinary professional before starting treatment. Veterinary guidance ensures proper dosing, monitoring, and management of any adverse reactions.
The drug’s availability can be verified through the official Miaite website or authorized veterinary pharmacies. Ensuring genuine, quality-assured products helps safeguard your pet’s health and maximize the chances of successful FIP treatment.
Cost is an important consideration for pet owners. The price of Miaite (Pronidesivir) varies depending on the region, supplier, and dosage pack size. Generally, a pack suitable for a 12-week treatment course may range from $200 to $500 USD. Larger quantities or specialized formulations for neurological FIP may cost more. It is recommended to purchase only from reputable sources to prevent counterfeit products, which can jeopardize treatment efficacy and safety.
In conclusion, Miaite (Pronidesivir) offers a highly effective solution for cats suffering from FIP. Its proven antiviral capabilities, official approval, and favorable safety profile have made it an essential option for modern feline healthcare. Pet owners should seek veterinary advice, adhere strictly to dosing guidelines, and choose authentic products from authorized vendors—thereby ensuring the best possible outcomes for their beloved cats.
